



| PART-I | Particulars | Standalone Quarter ended | | | Standalone year ended | | | Consolidated year ended | |
|---|---|---|---|---|---|--|---|--|--|
| | | March 31, 2014 | December 31, 2013 | March 31, 2013 | March 31, 2014 | March 31, 2013 | March 31, 2014 | March 31, 2013 | |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | |
| 1 | a) Income from Operations b) Other Operating Income Net Income from Operations | 2,702.16 38.77 2,740.93 | 2,669.48 10.21 2,679.69 | 2,399.86 48.87 2,448.72 | 10,770.01 67.92 10,837.93 | 9,922.81 152.30 9,845.11 | 10,770.01 67.92 10,837.93 | 9,922.81 152.30 9,845.11 | |
| 2 | a) Drugs and Consumables b) Employee Cost c) Professional Charges-Doctors d) Clinical Establishment Fee e) Net Depreciation and amortization f) Other Expenditure Total Expenditure | 538.98 378.50 669.92 417.56 52.05 480.81 2,477.82 | 555.99 361.91 656.19 414.66 49.07 480.58 2,528.41 | 485.72 338.12 619.95 396.71 45.77 412.28 2,288.63 | 2,305.25 1,431.32 2,610.19 1,667.26 1,999.27 1,932.88 10,146.17 | 2,025.60 1,379.08 2,467.58 1,667.26 249.04 2,324.68 8,888.55 | 2,305.25 1,463.14 2,573.62 1,667.26 199.27 1,934.93 10,143.47 | 2,025.60 1,413.22 2,426.25 730.57 249.04 2,036.13 8,882.87 | |
| 3 | Profit from operations before other Income, Interest & exceptional items (1-2) | 293.11 | 181.28 | 160.19 | 691.66 | 956.56 | 694.36 | 962.30 | |
| 4 | Other Income | 159.15 | 167.88 | 138.85 | 661.43 | 278.20 | 690.25 | 278.20 | |
| 5 | Profit before Interest & Exceptional Items (3 + 4) | 432.26 | 349.16 | 299.04 | 1,353.09 | 1,236.76 | 1,384.61 | 1,240.50 | |
| 6 | Finance Cost | 9.98 | 13.06 | 7.90 | 46.73 | 80.04 | 45.73 | 80.04 | |
| 7 | Profit from ordinary activities after Finance Cost but before Exceptional Items and Tax (5 - 6) | 422.28 | 305.80 | 281.14 | 1,307.36 | 1,156.72 | 1,338.88 | 1,160.46 | |
| 8 | Exceptional Items | - | - | - | - | 353.28 | - | 392.77 | |
| 9 | Interest Income (Refer Note 4 below) | - | - | - | - | 353.28 | - | 392.77 | |
| 10 | Profit from Ordinary Activities Before Tax | 422.28 | 305.80 | 281.14 | 1,307.36 | 1,510.00 | 1,338.88 | 1,553.23 | |
| 11 | Tax expense | 143.51 | 104.06 | 93.88 | 457.58 | 492.58 | 461.32 | 505.94 | |
| 12 | Net Profit from ordinary activities after Tax | 278.77 | 201.74 | 187.26 | 855.78 | 1,017.42 | 877.56 | 1,047.29 | |
| 13 | Extra Ordinary Items Profit on Sale of Clinical Establishment Business (Net of Tax expenses of Rs. 839.51 Lakhs) (Refer note 5 and 6 below) Net Profit after tax | 278.77 | 201.74 | (37.09) 180.23 | 855.78 | 3,900.54 4,317.96 | 877.56 | 3,300.54 4,347.83 | |
| 14 | Paid up Equity Share Capital (Face Value Rs:10 each) | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | |
| 15 | Reserves excluding Revaluation Reserves | 1.50 | 1.08 | 1.01 | 4.60 | 5.47 | 4.72 | 5.83 | |
| 16 | Earnings Per Share (EPS) - Basic (Rs.) - Before Extraordinary Items - After Extraordinary Items | 1.50 1.50 1.50 | 1.08 1.08 1.08 | 0.81 1.00 0.81 | 4.60 4.50 4.50 | 23.20 5.46 23.18 | 4.72 4.72 4.72 | 5.83 5.62 23.36 | |
| 17 | Earnings Per Share (EPS) - Diluted (Rs.) - Before Extraordinary Items - After Extraordinary Items | 1.50 1.50 1.50 | 1.08 1.08 1.08 | 1.00 0.81 | 4.50 4.50 | 5.46 23.18 | 4.72 4.72 | 5.62 23.32 | |
| PART-II | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| A | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| 1 | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| PARTICULARS OF SHARE HOLDINGS | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| Public Shareholding | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| - Number of Shares | | 68,41,857 | 68,41,857 | 68,41,857 | 68,41,857 | 68,41,857 | 68,41,857 | 68,41,857 | |
| - Percentage of shareholding | | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | |
| 2 | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| Promoters and promoters group Shareholding | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| a) Pledged / Encumbered | | NIL | NIL | NIL | NIL | NIL | NIL | NIL | |
| - No. of Shares | | - | - | - | - | - | - | - | |
| - % of Shares (as a % of total shareholding of promoter and promoter group) | | - | - | - | - | - | - | - | |
| b) Non-Encumbered | | - | - | - | - | - | - | - | |
| - No. of Shares | | 1,17,52,402 | 1,17,52,402 | 1,17,52,402 | 1,17,52,402 | 1,17,52,402 | 1,17,52,402 | 1,17,52,402 | |
| - % of Shares (as a % of total shareholding of promoter and promoter group) | | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | |
| - % of Shares (as a % of total share capital of the company) | | 63.20% | 63.20% | 63.20% | 63.20% | 63.20% | 63.20% | 63.20% | |
| B | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| INVESTOR COMPLAINTS | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | | [Not Annualised] | |
| Particulars | | Quarter ended March 31, 2014 | | Quarter ended March 31, 2014 | | Quarter ended March 31, 2014 | | Quarter ended March 31, 2014 | |
| Pending at the beginning of the quarter | | NIL | | NIL | | NIL | | NIL | |
| Received during the quarter | | 3 | | 3 | | 3 | | 3 | |
| Disposed off during the quarter | | 2 | | 2 | | 2 | | 2 | |
| Remaining unresolved at the end of the quarter | | 1 | | 1 | | 1 | | 1 | |



NOTES:

| 1 STATEMENT OF ASSETS AND LIABILITIES | | Standalone | | Consolidated | |
|---------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--|
| Particulars | As at March 31, 2014 (Audited) | As at March 31, 2013 (Audited) | As at March 31, 2014 (Audited) | As at March 31, 2013 (Audited) | |
| I. EQUITY AND LIABILITIES | | | | | |
| Shareholders' funds | 8,422.91 | 7,675.92 | 8,481.02 | 7,712.26 | |
| Share capital | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | |
| Reserves and surplus | 6,561.96 | 5,814.97 | 6,620.07 | 5,851.31 | |
| Non-current liabilities | 74.26 | 63.01 | 74.26 | 63.01 | |
| Deferred tax liabilities (net) | - | 63.01 | 74.26 | 63.01 | |
| Long term provisions | - | - | - | - | |
| Current liabilities | 1,575.05 | 1,241.30 | 1,594.51 | 1,306.58 | |
| Trade payables | 1,028.55 | 865.88 | 1,030.64 | 887.41 | |
| Other current liabilities | 377.10 | 234.77 | 392.45 | 286.75 | |
| Short-term provisions | 169.39 | 120.57 | 171.42 | 122.42 | |
| Total | 10,072.22 | 8,980.23 | 10,145.79 | 9,081.85 | |
| II. ASSETS | | | | | |
| Non-current assets | 1,844.06 | 1,752.51 | 1,954.10 | 1,816.07 | |
| Tangible assets | 1,743.33 | 1,728.04 | 1,743.33 | 1,728.04 | |
| Intangible assets | 19.83 | 8.87 | 19.83 | 8.87 | |
| Capital work in progress | 64.23 | - | 64.23 | - | |
| Non-current investments | 5.00 | 5.00 | - | - | |
| Deferred tax asset | - | - | 0.96 | - | |
| Long term loans and advances | 11.67 | 10.60 | 125.75 | 78.45 | |
| Current assets | 8,228.16 | 7,227.72 | 8,195.69 | 7,265.78 | |
| Inventories | 26.53 | 39.43 | 26.53 | 39.43 | |
| Trade receivables | 390.48 | 320.65 | 390.48 | 320.65 | |
| Cash and cash equivalents | 1,014.87 | 292.22 | 1,016.31 | 300.50 | |
| Short term loans and advances | 6,308.78 | 5,681.87 | 6,268.81 | 5,742.55 | |
| Other current assets | 487.10 | 913.55 | 493.16 | 962.65 | |
| Total | 10,072.22 | 8,980.23 | 10,145.79 | 9,081.85 | |

- 1 The above Audited Financial results have been reviewed by the Audit, Risk and Controls Committee, approved and taken on record by the Board of Directors in their meeting held on April 28, 2014.
- 2 The Company operates in one reportable segment in terms of Accounting Standard 17.
- 3 Interest Income aggregating Rs. 353.28 lakhs during the previous year ended March 31, 2013 earned on Inter-corporate deposit placed out of advance money received from Fortis Health Management Limited (FHML) towards sale of Clinical Establishment Business* (CEB) upto October 16, 2012, being the effective date of transfer of the CEB has been disclosed as an exceptional item and the related interest income aggregating to Rs.255.37 lakhs for the year pertaining to the period subsequent to October 16, 2012 has been included as a part of other income.
- 4 During the year ended March 2013, the company had completed the sale of its Clinical Establishment Business to Fortis Health Management Limited (FHML) (collectively, 'the parties') pursuant to the Business Transfer Agreement (BTA) dated August 27, 2012. Accordingly the net assets of Rs.2,308.93 lakhs of Clinical Establishment business had been transferred as a going concern on a slump sale basis effective October 17, 2012 for an aggregate consideration of Rs.7,000 lakhs. The net profit aggregating Rs.3,300.54 lakhs (net of tax expense- Rs.839.51 lakhs) arising from the sale of the said business has been disclosed as an 'extraordinary item'.
- 5 Extraordinary expense in the quarter ended March 31, 2013 of Rs. 37.03 lakhs (net of tax benefits- Rs.10.22 lakhs) represents additional stamp duty cost incurred on the transfer of land in respect of the sale of CEB.
- 6 During the current year, the board has declared an Interim Dividend of 50 paise per share in its meeting held on August 30, 2013.
- 7 The amount for the quarter ended March 31, 2014 have been derived as a balancing figure between the amounts as per the annual audited accounts and the year to date results upto December 31, 2013.
- 8 Previous period figures have been regrouped, wherever considered necessary.



By Order of the Board
 For and on Behalf of Board of Directors

 V. Vijayarathna
 Whole Time Director

Place: Chennai
 Date: April 28, 2014

PRESS RELEASE

FORTIS MALAR REPORTS Q4FY14 REVENUE AT RS 27.41 CR, +12%

OPERATING PROFIT FOR THE QUARTER AT RS 3.15 CR, +61%

FY14 CONSOLIDATED REVENUE AT RS 108.38 CR, +10%

OPERATING PROFIT FOR FY14 AT RS 8.94 CR

Chennai, April 28, 2014: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery service provider in India, today announced its results for the quarter ended March 31, 2014 and for the full year ended March 31, 2014.

Commenting on the results Mr. Aditya Vij, Chairman, Fortis Malar Hospitals Limited, said, “The hospital has established itself as a distinctive tertiary care medical services facility in Chennai. It has been setting new benchmarks in medical care by continually undertaking high end and complex surgeries, particularly in cardiology, neurology and mother and child care. I am pleased with the results and the medical outcomes at the hospital and am confident that we will continue to deliver world class clinical programmes, in the future as well.”

Key financial highlights for Q4 FY2014

- Fortis Malar Hospitals reported operating revenue of Rs 27.41 Cr, a growth of 12% over the corresponding quarter of the previous year.
- Operating profit for the quarter stood at Rs 3.15 Cr, witnessing a growth of 61% over the corresponding quarter of the previous year.
- Profit before tax (before exceptional items) stood at Rs 4.22 Cr compared to Rs 2.81 Cr in the corresponding quarter of last year.
- Net profit during the quarter was at Rs 2.79 Cr compared to Rs.1.50 Cr reported during the corresponding period, last fiscal.
- Fortis Malar’s revenue growth was mainly driven by better performances in CTVS, Orthopedics, Renal, Gastroenterology, Dialysis and Health check programmes, which grew by 31%, 68%, 68%, 84%, 27% and 23% respectively.

Key financial highlights for FY2014

- Fortis Malar reported consolidated operating revenue for the year ended March 31, 2014 of Rs 108.21 Cr, a growth of 10% over the previous year.
- Consolidated operating profit for the year stood at Rs 8.98 Cr compared to Rs 12.11 Cr in the previous year.
- Profit before tax and exceptional items stood at Rs 13.14 Cr compared to Rs 11.60 Cr in the corresponding quarter of last year.
- Net profit for the year was at Rs 8.80 Cr

Operational Highlights for Q4 2014

- During the quarter, our highly qualified medical teams at the hospital continued to perform rare surgeries. Few of them listed below.
 - The cardiology team at Fortis Malar successfully performed Five heart transplants during the quarter, which included an LVAD (Left ventricular Assist Device), an HVAD (Heart ware Ventricular Assist Device), and three donor human heart.
 - 85 years male diagnosed as ‘Ca Head of Pancreas’ successfully underwent Whipples/triple bye pass surgery.
 - 40 years Male with Gastritis/reflux, complaint of orthopnea admitted with obesity/cholelithiosis, umbilical hernia underwent Lap Roux EN Y gastric bypass, Lap Cholecystectomy open umbilical hernioplasty.
 - 61 Years old patient had rupture of supra clinodial aneurysm in brain underwent craniotomy for clipping of aneurysm.

Corporate Social Responsibility

Playing its part as a good social corporate citizen, Fortis Malar has been involved in activities that contribute to society. The hospital actively engages with the local community, at a meaningful level and organised:

- Health awareness talks, health checkups and free Cardiac camps at various corporate and Government organizations

- The hospital extended its Heart Saver programme by organizing multiple Free CPR training sessions for the local community. These sessions witnessed participation of over 700 people. A special session was also conducted for police personnel at the Joint Commissioner’s Office at St. Thomas Mount.
- On the occasion of International Women’s Day, Fortis Malar Hospital saluted the spirit of the successful woman and advocated the messages of health as key to career and life. A series of activities for women including a special health check package, health talks and an awareness campaign on radio was commissioned.
- The hospital roped in over 1000 people to pledge their support to the cause of Epilepsy on the occasion of Purple day. Special epilepsy investigation packages and health awareness talks were also organized at the hospital.

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital’s Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty. Currently, the company operates its healthcare delivery services in India, Singapore, Dubai, Mauritius and Sri Lanka with 66 healthcare facilities (including projects under development), over 10,000 potential beds and approx. 260 diagnostic centres.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors,

which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Ms. P.S. Ramya Gourri

Executive PR & Communications

Fortis Malar Hospitals Ltd

Mobile: 8939831218

ramya.gourri@fortishealthcare.com

Sumit Jain

K2 Communications Pvt Ltd

Mobile: 9886021715

Sumit.jain@k2communications.in